1. Home
  2. CRNX

as 03-28-2025 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Founded: 2008 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 5.2B IPO Year: 2018
Target Price: $73.36 AVG Volume (30 days): 937.9K
Analyst Decision: Strong Buy Number of Analysts: 12
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.69 EPS Growth: N/A
52 Week Low/High: $31.84 - $62.53 Next Earning Date: 05-08-2025
Revenue: $1,039,000 Revenue Growth: -74.11%
Revenue Growth (this year): 394.51% Revenue Growth (next year): 699.82%

CRNX Daily Stock ML Predictions

Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Struthers Richard Scott CRNX President & CEO Mar 19 '25 Sell $34.50 17,338 $593,016.96 330,022
Pizzuti Dana CRNX Chief Med and Dev Officer Mar 19 '25 Sell $34.50 2,515 $86,021.37 72,360
Betz Stephen F. CRNX Chief Scientific Officer Mar 19 '25 Sell $34.50 5,770 $197,352.96 108,588
Pizzuti Dana CRNX Chief Med and Dev Officer Feb 3 '25 Sell $39.07 5,000 $195,350.00 72,360
Pizzuti Dana CRNX Chief Med and Dev Officer Jan 3 '25 Sell $52.09 15,000 $781,350.00 72,360

Share on Social Networks: